Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment

Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?

(2015) Marlies de Ligt et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes

(2015) Morten Møller Poulsen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial

(2015) Shihui Chen et al.   DIGESTIVE AND LIVER DISEASE

P1044 : Randomised, placebo-controlled clinical trial: Long-term resveratrol treatment for non-alcoholic fatty liver disease

(2015) S. Heebøll et al.   JOURNAL OF HEPATOLOGY

Effect of resveratrol on experimental non-alcoholic steatohepatitis

(2015) Sara Heebøll et al.   PHARMACOLOGICAL RESEARCH

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

(2014) Veronique S. Chachay et al.   Clinical Gastroenterology and Hepatology

High-fat and high-cholesterol diet rapidly induces non-alcoholic steatohepatitis with advanced fibrosis in Sprague-Dawley rats

(2014) Mayuko Ichimura et al.   HEPATOLOGY RESEARCH

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

(2014) Forouzan Faghihzadeh et al.   NUTRITION RESEARCH

Resveratrol and cardiovascular health – Promising therapeutic or hopeless illusion?

(2014) Philip Chiu-Tsun Tang et al.   PHARMACOLOGICAL RESEARCH

The resveratrol fiasco

(2014) Francesco Visioli   PHARMACOLOGICAL RESEARCH

Effects of resveratrol and other polyphenols in hepatic steatosis

(2014) Leixuri Aguirre   WORLD JOURNAL OF GASTROENTEROLOGY

Evolving aspects of liver transplantation for nonalcoholic steatohepatitis

(2013) Michael Charlton   Current Opinion in Organ Transplantation

Extrahepatic complications of nonalcoholic fatty liver disease

(2013) Matthew J. Armstrong et al.   HEPATOLOGY

Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation

(2013) João Marcus Oliveira Andrade et al.   NUTRITION

Sulfate Metabolites Provide an Intracellular Pool for Resveratrol Generation and Induce Autophagy with Senescence

(2013) K. R. Patel et al.   Science Translational Medicine

High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition

(2012) M. M. Poulsen et al.   DIABETES

Nonalcoholic fatty liver disease in Asia: A story of growth

(2012) Vincent Wai-Sun Wong   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning

(2012) Juliana G. Franco et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance

(2012) Jill P. Crandall et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Are sirtuins viable targets for improving healthspan and lifespan?

(2012) Joseph A. Baur et al.   NATURE REVIEWS DRUG DISCOVERY

Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet

(2012) Morten Møller Poulsen et al.   NUTRITION RESEARCH

Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress

(2011) S. Gómez-Zorita et al.   BRITISH JOURNAL OF NUTRITION

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

(2011) Silvie Timmers et al.   Cell Metabolism

Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis

(2010) V. A. Brown et al.   CANCER RESEARCH

Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients

(2010) K. R. Patel et al.   CANCER RESEARCH

Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects

(2010) Charles la Porte et al.   CLINICAL PHARMACOKINETICS

Safety studies conducted on high-purity trans-resveratrol in experimental animals

(2009) Lonnie D. Williams et al.   FOOD AND CHEMICAL TOXICOLOGY

Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase

(2008) Jing SHANG et al.   ACTA PHARMACOLOGICA SINICA

Resveratrol inhibits nonalcoholic fatty liver disease in rats

(2008) Luis Bujanda et al.   BMC GASTROENTEROLOGY

Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet

(2008) Jiyun Ahn et al.   JOURNAL OF HEPATOLOGY

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL